Skip to main content

Protalix BioTherapeutics, Inc. (PLX) Stock Forecast

Data as of May 9, 2026

Healthcare · Current price $1.93 (-2.53%)

Consensus Target
Upside
Analysts
2
Rating
Buy(2.00)

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

PLX vs Sector & Market

MetricPLXHealthcare AvgLarge Cap Avg
Analyst Rating2.002.242.41
Analyst Count2819
Target Upside+1708.8%+16.4%
P/E Ratio-25.213.3227.60

Revenue Estimates

PeriodLowAvgHigh#
2026-06-30$38M$38M$38M1
2026-09-30$14M$14M$14M1
2026-12-31$15M$15M$15M1
2027-03-31$16M$16M$16M1
2027-06-30$18M$18M$18M1
2027-09-30$20M$20M$20M1
2027-12-31$23M$23M$23M1

EPS Estimates

PeriodLowAvgHigh#
2026-06-30$0.27$0.27$0.271
2026-09-30$-0.01$-0.01$-0.011
2026-12-31$0.01$0.01$0.011
2027-03-31$0.01$0.01$0.011
2027-06-30$0.01$0.01$0.011
2027-09-30$0.04$0.04$0.041
2027-12-31$0.08$0.08$0.081

Frequently Asked Questions

What is the analyst consensus for PLX?

The consensus among 2 analysts covering Protalix BioTherapeutics, Inc. (PLX) is Buy with an average price target of N/A.

How many analysts cover PLX?

2 analysts have issued ratings for Protalix BioTherapeutics, Inc. in the past 12 months.

Is PLX a buy or sell right now?

Based on 2 analyst ratings, PLX has a consensus rating of Buy (2.00/5) with a N/A upside to the consensus target of N/A.

What are the earnings estimates for PLX?

Analysts estimate PLX will report EPS of $0.27 for the period ending 2026-06-30, with revenue estimated at $38M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.